Metformin use improves the survival of diabetic combined small-cell lung cancer patients
- 16 May 2015
- journal article
- Published by Springer Science and Business Media LLC in Tumor Biology
- Vol. 36 (10), 8101-8106
- https://doi.org/10.1007/s13277-015-3549-1
Abstract
Metformin has been reported having potential anticancer effect on kinds of solid tumors, but its role in combined small-cell lung cancer (C-SCLC) remains indistinct. This study aimed to explore whether metformin use has a prognosis benefit in diabetic C-SCLC patients. A total of 259 C-SCLC patients with diabetes were enrolled in our study. The clinicopathological parameters and survival data were collected and analyzed. The correlation between metformin use and clinicopathological characters was analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of metformin use for C-SCLC. The metformin was used in 120 (46.3 %) patients. Our data showed that the metformin use decreased C-SCLC recurrence rate (p = 0.001). The median overall survival (OS) and disease-free survival (DFS) were significantly better in the metformin use group compared to non-metformin group (OS 19.0 vs 11.5 months, p p p = 0.001 vs p = 0.018). The metformin use improved the long-term outcome of C-SCLC patients with diabetes, which might be considered a potential useful prognostic indicator and anticancer drug.Keywords
This publication has 31 references indexed in Scilit:
- Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: A meta-analysis of observational studiesOral Oncology, 2015
- Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with MetforminAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Attenuating Tumour Angiogenesis: A Preventive Role of Metformin against Breast CancerBioMed Research International, 2015
- Metabolic Syndrome and Breast Cancer: Is There a Link?Breast Care, 2014
- Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular CarcinomaClinical Cancer Research, 2013
- Molecular mechanism of action of metformin: old or new insights?Diabetologia, 2013
- Mortality After Incident Cancer in People With and Without Type 2 DiabetesDiabetes Care, 2012
- Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patientsAnnals Of Oncology, 2011
- Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancerCancer, 2011
- Mixed Small Cell and Non-Small Cell Lung CancerChest, 1986